Education
About Us
Working with TipRanks
Follow Us
Taysha Gene Therapies (TSHA)
NASDAQ:TSHA
TSHA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.17 - $4.32
Previous CloseN/A
Volume273.02K
Average Volume (3M)2.06M
Market Cap
$284.95M
Enterprise Value$279.02M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.84
Next Earnings
May 07, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding205,001,630
10 Day Avg. Volume2,938,198
30 Day Avg. Volume2,064,121
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)40.35
Price to Cash Flow (P/CF)-4.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit33.48
Enterprise Value/Ebitda-3.17
Forecast
1Y Price Target
$6.63Price Target Upside426.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Taysha Gene Therapies News
See All TSHA News
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressTaysha Gene Therapies made significant progress in regulatory interactions and announced a clean bill of safety for the six high-dose patients treated.
Financial StandingThe recent ~14.4M share offering at $2.25/sh and pre-funded warrants should net the company ~$70.5M, providing runway into Q426.
Product EfficacyTSHA-102 has achieved similar efficacy at early time points to NGN-401 despite being given at a lower dose and administered in a less invasive way.
Regulatory ProgressProgress in FDA discussions and the upcoming update on trial design and primary endpoint could be a highly positive catalyst.
Bears Say
Clinical Data ConcernsRecent stock reaction following initial pediatric data and longer-term adolescent/adult data for TSHA-102 has raised questions around clinical benefit and approvable endpoints.
Stock Market ReactionRecent stock reaction following initial pediatric data and longer-term adolescent/adult data for TSHA-102 has raised questions around clinical benefit and approvable endpoints.
---
Ownership Overview
16.18% Insiders
13.36% Mutual Funds
36.34% Other Institutional Investors
24.61% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TSHA FAQ
What was Taysha Gene Therapies’s price range in the past 12 months?
Taysha Gene Therapies lowest stock price was $1.17 and its highest was $4.32 in the past 12 months.
What is Taysha Gene Therapies’s market cap?
Taysha Gene Therapies’s market cap is $284.95M.
When is Taysha Gene Therapies’s upcoming earnings report date?
Taysha Gene Therapies’s upcoming earnings report date is May 07, 2025 which is in 34 days.
How were Taysha Gene Therapies’s earnings last quarter?
Taysha Gene Therapies released its earnings results on Feb 26, 2025. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.081 by $0.011.
Is Taysha Gene Therapies overvalued?
According to Wall Street analysts Taysha Gene Therapies’s price is currently Undervalued.
Does Taysha Gene Therapies pay dividends?
Taysha Gene Therapies does not currently pay dividends.
What is Taysha Gene Therapies’s EPS estimate?
Taysha Gene Therapies’s EPS estimate is -0.09.
How many shares outstanding does Taysha Gene Therapies have?
Taysha Gene Therapies has 205,001,630 shares outstanding.
What happened to Taysha Gene Therapies’s price movement after its last earnings report?
Taysha Gene Therapies reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.081. Following the earnings report the stock price went down -4.706%.
Which hedge fund is a major shareholder of Taysha Gene Therapies?
Currently, no hedge funds are holding shares in TSHA
---
Taysha Gene Therapies Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.63 (426.19% Upside)
$6.63 (426.19% Upside)
Blogger Sentiment
Bullish
TSHA Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 34.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.45%
12-Months-Change
Fundamentals
Return on Equity
-121.94%
Trailing 12-Months
Asset Growth
3.53%
Trailing 12-Months
Company Description
Taysha Gene Therapies
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
---
TSHA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in the TSHA-102 program, including the completion of Part A dosing and encouraging safety and functional outcomes, alongside strong financial positioning. Despite increased R&D expenses and a net loss, the overall sentiment is positive due to the promising clinical and regulatory advancements.Read More>---
TSHA Stock 12 Month Forecast
Average Price Target
$6.63
▲(426.19% Upside)
Technical Analysis
Bluebird Bio
―
uniQure
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering TSHA
1 Year
1 Year Success Rate
7/21 ratings generated profit
1 Year Average Return
+9.62%
reiterated a buy rating 5 months ago
Copying Jack Allen's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +9.62% per trade.
---